ABSOLUTE EASI TARGET IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: ANALYSIS OF DATA FROM THE MEASURE UP 1 AND 2 STUDIES

被引：0
|
作者：
Prajapatil, Vimal [1 ,2 ,3 ,4 ,5 ,6 ]
Simpson, Eric L. [7 ]
Thyssen, Jacob P. [8 ]
Chovatiya, Raj [9 ]
Lane, Michael [10 ]
Teixeira, Henrique [10 ]
Calimlim, Brian [10 ]
Silverberg, Jonathan I. [11 ]
机构：
[1] Univ Calgary, Div Dermatol, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Sect Community Pediat, Dept Pediat, Calgary, AB, Canada
[3] Univ Calgary, Sect Pediat Rheumatol, Dept Pediat, Calgary, AB, Canada
[4] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[5] Dermatol Res Inst, Calgary, AB, Canada
[6] Prob Med Res, Calgary, AB, Canada
[7] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[8] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
[9] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA
[10] AbbVie Inc, N Chicago, IL USA
[11] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P4.17
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [1] The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies
    Cather, Jennifer
    Magnolo, Nina
    Cameron, Michael
    Calimlim, Brian
    Lane, Michael
    Hays, Stephanie
    Gamelli, Amy
    Woo, Yu Ri
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [2] The multidimensional burden of moderate-to-severe atopic dermatitis: a pooled analysis of baseline data from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Silverberg, J. I.
    Thyssen, J. P.
    Costanzo, A.
    Calimlim, B. M.
    Tenorio, A. R.
    Chen, N.
    Gooderham, M. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E126 - E127
  • [3] Upadacitinib in moderate-to-severe atopic dermatitis: combined safety analysis of phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Guttman-Yassky, Emma
    Irvine, A. D.
    Silverberg, J. I.
    Papp, K. A.
    Paller, A. S.
    Waterhouse, B.
    Tenorio, A. R.
    Ladizinski, B.
    Chu, A. D.
    Liu, J.
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E123 - E124
  • [4] Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
    Guttman-Yassky, Emma
    Irvine, Alan D.
    Silverberg, Jonathan I.
    Papp, Kim A.
    Paller, Amy S.
    Waterhouse, Brian
    Tenorio, Allan R.
    Ladizinski, Barry
    Chu, Alvina D.
    Liu, John
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB129 - AB129
  • [5] Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies
    Blauvelt, Andrew
    Silverberg, Jonathan, I
    Calimlim, Brian M.
    Liu, Yingyi
    Platt, Andrew
    Thyssen, Jacob P.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [6] Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis
    Thyssen, Jacob P.
    Bieber, Thomas
    Kleyn, C. Elise
    Nosbaum, Audrey
    Grond, Susanne
    Petto, Helmut
    Riedl, Elisabeth
    Wollenberg, Andreas
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [7] Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials
    Paller, Amy S.
    Ladizinski, Barry
    Mendes-Bastos, Pedro
    Siegfried, Elaine
    Soong, Weily
    Prajapati, Vimal H.
    Lio, Peter
    Thyssen, Jacob P.
    Simpson, Eric L.
    Platt, Andrew M.
    Raymundo, Eliza M.
    Liu, Jianzhong
    Calimlim, Brian M.
    Huang, Xiaohong
    Gu, Yihua
    Hu, Xiaofei
    Yang, Yang
    Su, John C.
    Zheng, Min
    Yamamoto-Hanada, Kiwako
    Teixeira, Henrique D.
    Irvine, Alan D.
    JAMA DERMATOLOGY, 2023, 159 (05) : 526 - 535
  • [8] Achieving incrementally greater skin improvement thresholds with upadacitinib in moderate-to-severe atopic dermatitis: a pooled analysis of two phase III studies (Measure Up 1 and Measure Up 2)
    Reich, K.
    Langley, R. G.
    Calimlim, B. M.
    Teixeira, H. D.
    Zeng, J.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E131 - E132
  • [9] Rapid skin improvement with upadacitinib with or without topical corticosteroids in moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Simpson, E. L.
    Warren, R. B.
    Eichenfield, L. F.
    Katoh, N.
    Hu, X.
    Zeng, J.
    Calimlim, B. M.
    Tenorio, A. R.
    Teixeira, H. D.
    De Bruin-Weller, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E118 - E119
  • [10] Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase III clinical trials
    Paller, A. S.
    Mendes-Bastos, P.
    Eichenfield, L. F.
    Soong, W.
    Lio, P.
    Prajapati, V. H.
    Platt, A. M.
    Teixeira, H. D.
    Liu, J.
    Ladizinski, B.
    Thyssen, J. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E128 - E129
12345